Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: AUY922

First Posted Date: 2010-05-28

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT01132625

Locations: 🇯🇵
Novartis Investigative Site, Sunto-gun, Shizuoka, Japan

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Phase 1

Terminated

Conditions: Metastatic Breast Cancer
HER2+ Breast Cancer

Interventions: Drug: BKM120
Drug: Trastuzumab
Drug: Capecitabine

First Posted Date: 2010-05-28

Last Posted Date: 2016-08-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 72

Registration Number: NCT01132664

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Sarah Cannon Research Institute Sarah Cannon Cancer Center SC, Nashville, Tennessee, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

and more 5 locations

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Phase 2

Completed

Conditions: Plaque-type Psoriasis

Interventions: Drug: AIN457
Drug: Placebo

First Posted Date: 2010-05-28

Last Posted Date: 2018-01-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 275

Registration Number: NCT01132612

Locations: 🇳🇴
Novartis Investigative Site, Ålesund, Norway

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

Phase 3

Terminated

Conditions: Visual Impairment Due to Diabetic Macular Edema

Interventions: Procedure: Active laser photocoagulation
Drug: Ranibizumab 0.5 mg
Drug: Sham injections

First Posted Date: 2010-05-27

Last Posted Date: 2012-08-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 128

Registration Number: NCT01131585

Locations: 🇩🇪
Novartis Investigative Site, Würzburg, Germany

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

Phase 4

Terminated

Conditions: Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
CML
Philadelphia Chromosome Positive (Ph+)

Interventions: Drug: nilotinib

First Posted Date: 2010-05-26

Last Posted Date: 2021-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT01131325

Locations: 🇺🇸
Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas, Nevada, United States
🇺🇸
Cancer Center of the High Plains, Amarillo, Texas, United States
🇺🇸
Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2), Dallas, Texas, United States

Efficacy of QAX576 in Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Biological: QAX576

First Posted Date: 2010-05-25

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 259

Registration Number: NCT01130064

Locations: 🇷🇺
Novartis Investigative Site, Yaroslavl, Russian Federation

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

Phase 4

Completed

Conditions: First or Second Line HER2-negative Breast Cancer
Metastatic Disease Without Bone Metastasis

Interventions: Drug: Standard Therapy
Drug: Zoledronic acid

First Posted Date: 2010-05-24

Last Posted Date: 2014-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT01129336

Locations: 🇺🇸
Loma Linda University Loma Linda Cancer Center, Loma Linda, California, United States
🇺🇸
Wilshire Oncology Medical Group, La Verne, California, United States
🇺🇸
Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States

and more 30 locations

Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients

Phase 2

Completed

Conditions: Liver Transplantation

Interventions: Drug: MMF(1000mg bid) + tacrolimus + standard of care medications
Drug: sotrastaurin (200mg bid) + tacrolimus + standard of care medications
Drug: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications

First Posted Date: 2010-05-21

Last Posted Date: 2020-12-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT01128335

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Phase 3

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib

First Posted Date: 2010-05-20

Last Posted Date: 2017-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT01126892

Locations: 🇻🇪
Banco Municipal de Sangre, Caracas, Venezuela
🇨🇴
Hospital San José, Bogotá, Colombia, Bogota, Colombia

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Furosemide 60 mg
Drug: Aliskiren 150 mg
Drug: Placebo for Aliskiren
Drug: Aliskiren 300 mg

First Posted Date: 2010-05-18

Last Posted Date: 2012-09-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT01125514

Locations: 🇱🇹
Novartis Investigative Site, Vilnius, Lithuania

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy